Previous 10 | Next 10 |
2023-11-16 13:09:59 ET More on Unity Biotechnology Unity Biotechnology GAAP EPS of -$1.05 misses by $0.16 UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data...
2023-11-16 08:32:33 ET WaveDancer ( WAVD ) +108% Announces Merger Agreement with Firefly Neuroscience. HNR Acquisition ( HNRA ) +19% Announces Completion of its Business Combination by Acquisition of Pogo Resources, LLC; HNRA begins Managing and Operating...
Unity Biotechnology Inc. (UBX) is expected to report $-0.87 for Q3 2023
2023-11-14 01:01:35 ET More on Unity Biotechnology UNITY Biotechnology to exercise warrants for $4.38M in gross proceeds Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unit...
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023. ȁ...
2023-11-10 13:20:36 ET More on Unity Biotechnology Seeking Alpha’s Quant Rating on Unity Biotechnology Historical earnings data for Unity Biotechnology Financial information for Unity Biotechnology For further details see: UNITY Biotechnology to ex...
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY” or the “Company”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the entry into a definitive a...
Patients on combination treatment with UBX1325 and aflibercept from weeks 24-48 maintained vision gains achieved at week 24 on aflibercept alone, with greater vision improvement in patients with more severe disease Patients with prior anti-VEGF treatment and switched to UBX1325 monother...
2023-08-08 17:28:31 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q2 GAAP EPS of -$0.85 in-line. Cash, cash equivalents and marketable securities totaled $71.0 million as of June 30, 2023 compared with $94.8 million as of December 31, 2022. UNITY believes that ...
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We...
News, Short Squeeze, Breakout and More Instantly...
Unity Biotechnology Inc. Company Name:
UBX Stock Symbol:
NASDAQ Market:
Unity Biotechnology Inc. Website:
SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2024. "Our team r...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company develo...
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at t...